Trial Profile
A multicenter phase II study to evaluate safety and efficacy of glutadon once weekly (GDO) in patients with metastatic colorectal cancer resistant or intolerable to approved chemo- and molecular-targeted therapies
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Feb 2013
Price :
$35
*
At a glance
- Drugs PEG-glutaminase/diazo-oxo-L-norleucine (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 22 Jun 2011 New trial record